STOCK TITAN

Evofem Biosciences to Participate in Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a corporate presentation at 7:00 a.m. ET. The second is the Morgan Stanley Virtual Global Healthcare Conference on September 14, 2021, in a fireside chat at 12:30 p.m. ET. Both events will be webcast and available for 30 days on the company’s website. Evofem focuses on women's sexual and reproductive health, including innovative contraceptive solutions.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Sept. 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows: 

H.C. Wainwright 23rd Annual Global Investment Conference



Format:

Corporate presentation

Date:

Monday, September 13, 2021 

Time:

7:00 a.m. ET (4:00 a.m. PT)



Morgan Stanley Virtual Global Healthcare Conference



Format:

Fireside chat

Date:

Tuesday, September 14, 2021

Time:

12:30 – 1:00 p.m. ET (9:30 -10:00 a.m. PT)  

Webcasts of both events will be available through the Events section of the Evofem website at https://evofem.investorroom.com/events for 30 days.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.' For more information, please visit evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-investor-conferences-301367047.html

SOURCE Evofem Biosciences, Inc.

FAQ

What is Evofem Biosciences' participation in investor conferences in September 2021?

Evofem Biosciences' CEO Saundra Pelletier will present at two investor conferences: H.C. Wainwright on September 13, 2021, and Morgan Stanley on September 14, 2021.

What will happen at the H.C. Wainwright Conference?

At the H.C. Wainwright Conference on September 13, 2021, Evofem will give a corporate presentation starting at 7:00 a.m. ET.

What format will the Morgan Stanley Virtual Global Healthcare Conference take?

The Morgan Stanley Conference will feature a fireside chat on September 14, 2021, at 12:30 p.m. ET.

Where can I watch the webcasts of the investor conferences?

The webcasts of both conferences will be available for 30 days on the Evofem website under the Events section.

What is the focus of Evofem Biosciences?

Evofem Biosciences develops products for women's sexual and reproductive health, including hormone-free contraception and protection against STIs.

EVOFEM BIOSCIENCE INC

OTC:EVFM

EVFM Rankings

EVFM Latest News

EVFM Stock Data

1.00M
100.33M
0%
0.1%
10.98%
Biotechnology
Healthcare
Link
United States of America
San Diego